ClinicalTrials.gg
CompletedNCT05101408ETAT PSAUpdated Apr 12, 2022

Executive Training and Anomia Therapy in Chronic Post-stroke Aphasia

An observational study in Anomia and Post-stroke Aphasia, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by University Hospital, Montpellier · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Aphasia is a devastating acquired language impairment mainly caused by stroke, in which anomia is a quintessential clinical feature. If speech-language therapy (SLT) has been shown to be effective for persons with aphasia, the relative efficiency of one SLT strategy over another remains a matter of debate. The influential relationship between language, executive functions and aphasia rehabilitation outcomes has been addressed in a number of studies, but only few of them have studied the effect of adding an executive training to linguistic therapies.The aim of this study is to measure the efficiency of a protocol combining anomia therapy and executive training on naming skills and discourse in post-stroke aphasic persons at the chronic stage

02

Conditions studied

  • Anomia
  • Post-stroke Aphasia

Keywords

  • Aphasia
  • Speech-Language Therapy
  • Anomia
  • Executive functions
03

In context

Anomia

47 studies on the registry are indexed under Anomia; 9 are open to participants now.

Browse Anomia studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Person with post-stroke aphasia at the chronic stage, receiving SLT rehabilitation

Eligibility criteria

Inclusion criteria:

  • 18 \< age > 80 years
  • adult person with chronic post-stroke aphasia (> 6 months postonset)
  • receiving SLT rehabilitation 3 times a Week

Exclusion criteria:

  • presence of apraxia of speech
  • major impairment of comprehension
  • history of other neurological or psychiatric disease

Exclusion criteria:

  • presence of apraxia of speech
  • presence of major impairment of comprehension
  • presence of history of other neurological or psychiatric disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evolution of individual naming scores

    Evolution of individual naming scores during baseline and treatment phases Participants are asked to name pictures from a personal naming task constituted of 100 black and white pictures and scores are expressed as percent of correct responses (min 0, max 100): higher percents meaning a better outcome. A visual analysis of the evolution of these scores along the course of the treatment will be conducted.

    Time frame: 2 days

  2. Comparison of discourse

    Comparison of discourse scores before and after the treatment For each participant, four different samples of discourse are elicited before and after the treatment (picture description, personal narrative, book supported narrative, procedural information). The mean number of correct words per minute is then computed for each participant, and compared between the two time points, higher scores meaning a better outcome.

    Time frame: 2 days

Secondary outcomes

  1. Comparison of executive scores

    Comparison of executive scores before and after the treatment Executive scores are computed before and after treatment for each participant, from the Modified Card Sorting Test (Nelson, 1976), in which higher number of categories achieved means a better outcome, and from a verbal fluency task in which higher number of words produced in 2 minutes means a better outcome

    Time frame: 2 days

07

Study locations

1 site
  • Uhmontpellier
    Montpellier, 34295, France
08

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05101408
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Sep 1, 2021
Primary completion
Dec 1, 2021
Completion
Dec 30, 2021
Last update
Apr 12, 2022

Study contacts

Sylvie Moritz-Gasser
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion